The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study [see comments]

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study [see comments]

AIDS. 1990 Dec;4(12):1197-204. Unique Identifier : AIDSLINE MED/91207612
Kahn JO; Kaplan LD; Gambertoglio JG; Bredesen D; Arri CJ; Turin L; Kibort T; Williams RL; Lifson JD; Volberding PA; Department of Medicine, San Francisco General Hospital, CA 94110.

Abstract: A phase I dose-escalation study was performed to evaluate the safety and pharmacokinetics of a single intravenous infusion of GLQ223 in subjects with AIDS and AIDS-related complex (ARC). The active ingredient in GLQ223 is trichosanthin. Trichosanthin, imported from China, is the active drug in community-initiated treatment programs for patients with HIV infection. Eighteen subjects were enrolled, 10 with AIDS and eight with ARC. All subjects were monitored for tolerance and toxicity. Immunological and virological parameters were also followed. GLQ223 administration was not associated with notable toxicity with the exception of one subject who experienced a severe neurological adverse reaction. No consistent or sustained changes in CD4+ lymphocyte populations or HIV antigen levels were observed. Serum concentrations of GLQ223 that were comparable to concentrations shown to have antiviral activity in vitro were achieved transiently but may not have been maintained for a sufficient duration to exert antiretroviral effects. Further studies are indicated to determine pharmacodynamic properties of GLQ223, its optimal dosing schedule, and whether GLQ223 or related molecules will be useful in the treatment of HIV infection.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/IMMUNOLOGY/ PATHOLOGY Adult AIDS-Related Complex/*DRUG THERAPY/IMMUNOLOGY Brain/PATHOLOGY Dose-Response Relationship, Drug Drug Evaluation Human HIV Antigens/BLOOD Injections, Intravenous Magnetic Resonance Imaging Male Support, Non-U.S. Gov't T-Lymphocyte Subsets Trichosanthin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS/*THERAPEUTIC USE CLINICAL TRIAL JOURNAL ARTICLE

Comment in: AIDS 1990 Dec;4(12):1289-91
910830
M9180959

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .